Board Oversight Committee

Dr. Angelique Chan holds joint appointments as Associate Professor in the Signature Program in Health Services & Systems Research, Duke-NUS Medical School and the Department of Sociology, NUS. She is the Inaugural Executive Director of the Centre for Ageing Research & Education (CARE, Duke-NUS). Dr Chan obtained her undergraduate degree, BA (Sociology) from Reed College, her PhD (Sociology) from the University of California at Los Angeles as a Rockefeller Foundation PhD fellowship awardee, and a US National Institute of Aging Post-Doctoral degree at the University of Michigan.

Dr. Chan‘s current research examines disability transitions, mortality, and the effects of social support on health, caregiver burden, and use of long-term care services. She has published widely on aging issues in leading international journals including the Journal of American Geriatrics Society, Journal of Aging and Health, and Journal of Gerontology Series B: Social Sciences and book chapters. She is co-author of a book titled Ageing in Singapore: Service Needs & the State (Routledge 2006) and Co-editor of Ultra-low Fertility in Pacific Asia: Trends, Causes and Policy Issues (Routledge 2009).

Her international work includes working with collaborators from Japan and USA on caregiving, work and retirement, and disability transitions. She has consulted for various local Singapore governments entities and international bodies such as the UNESCAP, The World Bank and the Asian Development Bank.

1. Group Director, Research (Scientific), SingHealth
2. Executive Director, Singapore Eye Research Institute;
3. Deputy Medical Director, Singapore National Eye Centre
4. Professor, Yong Loo Lin School of Medicine, National University of Singapore
5. ‘Kwan Im Thong Hood Cho Temple’ Professor of Ophthalmology, Duke-NUS Medical School

Professor Aung obtained the Fellowships of the Royal College of Surgeons, Edinburgh and the Royal College of Ophthalmologists in 1997, and completed a glaucoma fellowship at SNEC in 2000. He then trained at the Institute of Ophthalmology, University College London and Moorfields Eye Hospital from 2000-2003; and was awarded a PhD in Molecular Genetics from UCL.

Professor Aung is a clinician scientist, with research interests in angle closure glaucoma and glaucoma genetics. With >600 publications, Professor Aung has been awarded >US$20 million in competitive research grant funding. He is a member of the Editorial Boards of Ophthalmology, Eye, Journal of Glaucoma, Progress in Retinal & Eye Research, and Graefe’s Archive for Clin Exp Ophthalmol; he is a past President of the World Glaucoma Association and serves as Board member of the Asia-Pacific Glaucoma Society.

Mr Beh Kian Teik is the Deputy Chief Executive Officer of the National Research Foundation. He is responsible for planning, reviewing, developing and implementing the national research, innovation and enterprise (RIE) strategies and governance frameworks, to grow and sustain a vibrant RIE ecosystem in Singapore. He plays an instrumental role in obtaining national consensus on research priorities, to guide long-term strategic R&D investment decisions by the NRF Board.

Kian Teik is concurrently the Executive Vice President of the Singapore Economic Development Board. He oversees EDB New Ventures. He works with corporate entrepreneurs with the passion and drive to create early stage ventures in Singapore. He has over twenty years’ experience of promoting FDI and building industries in the manufacturing and internationally tradeable services sectors.

Previously, he was responsible for EDB’s activities in innovation & industry incubation and led effort to foster industry-science linkages. In 2010, he was also the founding director of the Singapore Biomedical Sciences Industry Partnership Office, a unique inter-agency government organisation. In this role, he worked with senior Singapore scientists to partner industry to translate science to medicine, and with industry partners that desire to undertake R&D projects requiring the capabilities of multiple Singapore agencies, in basic sciences and clinical research.

Kian Teik joined EDB in February 1998 and has held roles of increasing responsibilities in EDB. His previous leadership roles included developing the biomedical sciences cluster, attracting European FDI from Europe and running the IT, planning, research and statistics operations. He is a Sundstrand-EDB and Glaxo-EDB scholar who graduated from the University of California, Berkeley with an MSc in Electrical Engineering, as well as a BSc in Electrical & Computer Engineering from the University of Illinois at Urbana-Champaign.

As Deputy Secretary (Technology) at MOH, Dr Cheong deploys technology against COVID-19, and is developing the health innovation ecosystem to achieve MOH’s 3 Beyonds – beyond healthcare to health; beyond the hospital to community, and beyond quality to value.

Prior to MOH, he was Deputy CEO of NRF, where he implemented the S$19 billion RIE 2020 plan and led an inter-agency effort to develop the S$25 billion RIE 2025 plan.

He served on the Boards of URA; ISEAS-Yusof Ishak Institute; NMRC; EDDC; DxD Hub; National Additive Manufacturing Programme; Singapore Food Story R&D Programme; Centre for Research & Development in Learning; and NRF Holdings.

Dr Cheong was Divisional Director (Planning) in MOE. Beyond educational policies, he shaped educational research at the National Institute of Education and led international benchmarking and partnership efforts. As Deputy Director (Manufacturing & Services) at MTI overseeing EDB, he led the Secretariat for the Economic Strategies Committee chaired by Senior Minister Tharman Shanmugaratnam. As Head Fiscal Strategy at Ministry of Finance, he shaped Singapore’s long-term fiscal sustainability.

As a Rhodes Scholar and PSC Scholar, he obtained his DPhil/MPhil in Economics from Oxford, and his S.B. in Chemical Engineering and S.B. in Economics from Massachusetts Institute of Technology respectively.

Dr. Daphne Khoo is the Deputy Director of Medical Services (Healthcare Performance Group) and concurrently, Executive Director of the Agency of Care Effectiveness (ACE), Ministry of Health, Singapore (MOH). The mission of ACE is to drive appropriate care in Singapore through the application of Health Technology Assessment.

Dr. Khoo is an endocrinologist by training and was previously Head of Endocrinology at Singapore General Hospital (SGH). From 2004 to 2011, she was the Director of Clinical Governance and Quality Management of the SingHealth cluster and also served as their Director of Enterprise Risk. She is a past-President of the Association of Women Doctors, Singapore as well as the Association of South East Asian Nations Federation of Endocrine Societies.

From 2011 to 2014, she worked in the private sector as a Chief Medical Officer managing healthcare facilities in 11 countries.

Dr Fidah Alsagoff is currently Joint Head of Enterprise Development Group and Head of Life Sciences at Temasek International Pte Ltd, where he has been since 2008.

He was previously a Partner at Innosight Ventures Private Limited, and prior to that, was Chief Executive Officer of MOH Holdings. His career also includes nearly a decade in social entrepreneurship where he started up several programs and enterprises catering to hitherto unmet healthcare needs of patients, with the latest enterprise being the establishment of the Singapore Cord Blood Bank.

Fidah graduated from the National University of Singapore with a Bachelors of Medicine and Surgery, and later with a Masters of Medicine in Public Health. He attended INSEAD on a Lee Kuan Yew Scholarship for post-graduate studies, and subsequently graduated with an Executive MBA (with distinction). As valedictorian of his EMBA class, he was awarded the Claude Janssen Prize.

Fidah currently serves on the Board of Trustees of the Singapore University of Technology and Design and on the Governing Board of the Duke-NUS Medical School.

Professor Sung received his medical degree (MBBS) from The University of Hong Kong, and conferred PhD in biomedical sciences by the University of Calgary and MD by The Chinese University of Hong Kong (CUHK). He holds fellowships from the Royal Colleges of Physicians of Edinburgh, Glasgow, London, and Australia, the American College of Gastroenterology, the American Gastroenterological Association, the Hong Kong College of Physicians, the Hong Kong Academy of Medicine and Academy of Sciences of Hong Kong (ASHK). He is an Academician of the Chinese Academy of Engineering of the People’s Republic of China and Academician of the International Eurasian Academy of Sciences.

He served as the Vice-Chancellor and President of the Chinese University of Hong Kong from 2010-2017 and the Chair of Worldwide Universities Network (WUN) in 2016-17. He is currently Emeritus Professor in Medicine of CUHK.

Professor Sung has published over 1000 full scientific articles in leading medical and scientific journals. He was listed as “Highly Cited Researchers”, released by the Clarivate Analytics, for the years 2018, 2019 and 2020. He has edited and authored around 30 books, as well as many chapters in major textbooks including the Oxford Textbook of Medicine (5th Ed.), Fordtran and Slanginger Textbook of Gastroenterology (7th Ed) and Yamada’s Textbook of Gastroenterology (4th Ed).

From 1 April 2021, Prof Sung assumed the role of Distinguished University Professor, Senior Vice President (Health & Life Sciences) and Dean, Lee Kong Chian School of Medicine at Nanyang Technological University, Singapore.

Professor Ng Huck Hui is the Assistant Chief Executive of the Biomedical Research Council, under the Agency for Science, Technology and Research.

Prof Ng is renowned in the field of gene regulation and genomics. His laboratory is developing diagnostic and therapeutics modalities for brain and liver diseases. Prof Ng had held several administrative positions. He was the Executive Director of the Genome Institute of Singapore and the Executive Director of the A*STAR Graduate Academy.

Prior to joining A*STAR, Prof Ng was a postdoctoral fellow with Harvard Medical School under the prestigious Damon Runyon-Walter Winchell Postdoctoral Fellowship. Prof Ng is renowned in the field of stem cells, having spent more than a decade in research to understand and uncover the intricacies of gene regulation and how they relate to cell biology. He was also the President for the Stem Cell Society Singapore, which is a major platform for educating the public on stem cell research. In 2016, Prof Ng was elected to be an Associate Member of the European Molecular Biology Organization, making him the only associate member to be based in Singapore. Most recently, Prof Ng was also elected as Fellow of the Singapore Academy of Science (SNAS).

In recognition of his scientific contributions, Prof Ng has received numerous local and international honours and awards, including the Young Scientist Award in 2004, Singapore Youth Award in 2005, National Science Award in 2007, Junior Chamber International (JCI) The Outstanding Young Persons Singapore Awards in 2009, Singapore Youth Award (Commendation Medal) in 2010, President’s Science Award (Team Award) in 2011, President’s Science Award (Team Award) in 2018 and The Public Administration Medal (Silver), National Day Awards 2019.

Outside of A*STAR, Prof Ng is very active in the local universities and organizations, and holds adjunct positions at the National University of Singapore (NUS) Yong Loo Lin School of Medicine, NUS Faculty of Science, Nanyang Technological University (NTU) School of Biological Sciences and LKC Medicine and the Singapore Eye Research Institute (SERI). He also sits on the Board of Consortium for Clinical Research and Innovation Singapore (CRIS) Pte Ltd, National Medical Research Council (NMRC), Science Centre Singapore and NUS High School.

A/Prof (Dr) Raymond Chua graduated from the Faculty of Medicine in National University of Singapore in 1997. He holds a Masters in Public Health (London School of Hygiene and Tropical Medicine, 2002) and is a Registered Public Health specialist and Fellow with the Academy of Medicine, Singapore.

His career spans both public service and private sector industry (as Managing Director of Eisai Clinical Research Singapore, and International Medical Director with Shire Pharmaceuticals). In 2012, A/Prof Chua was designated as Group Director of the Health Products Regulation Group in the Health Sciences Authority. Since 2017, he has joined the Ministry of Health as Group Director, Health Regulation Group to oversee and reform the regulations of healthcare services and premises in Singapore, so as to safeguard public health. He also holds other adjunct academic appointments, including an Adjunct Associate Professor in the Saw Swee Hock School of Public Health in National University of Singapore and Centre of Regulatory Excellence in Duke-NUS.

Roger Foo is the inaugural Zayed bin Sultan Al Nahyan Professor of Medicine at the NUS Yong Loo Lin School of Medicine, Director of the NUHS Cardiovascular Disease Translational Research Programme, Dy Director of the Cardiovascular Research Institute, Assistant Dean (Research), Head of the NUHS Clinician Scientist Academy, and Senior Consultant lead for the Cardiac Genetics Clinic, National University Heart Centre. He is a graduate of the Medical School at NUS, and spent 20 years abroad before returning to Singapore in 2013. His specialist training was undertaken at Kings College Hospital, London, and Addenbrooke’s Hospital, Cambridge. In 2003, he was awarded the Wellcome Trust Fellowship to pursue research at the Albert Einstein College of Medicine, New York, and returned to Cambridge in 2006 as a British Heart Foundation Fellow and Consultant Physician, before eventually returning to Singapore. His lab was the first to publish an epigenomic map of the failing human heart in 2012. More recently, his lab has published an in-depth analysis of the cardiac chromatin 3D organisation, and also reported the discovery of a long noncoding RNA, called Singheart, which regulates key cardiac gene expression. The approach of the lab is to deep dive into the epigenome of the heart, using advanced technology including single cell transcriptomics and Crispr-genome editing to explore frontiers, in continuing aspirations to discover novel avenues for therapies or biomarkers. Roger is also a keen advocate for the application of Next Generation sequencing based genomics to the clinic.